Swipe Left For English News
中国香港,
2025年12月24日
药明生物（WuXi Biologics, 2269.HK）持续引领可持续发展与信息披露标准。公司荣登2025年香港ESG报告大奖（HERA）“ESG披露优秀榜单”，这一殊荣标志着药明生物在透明披露和负责任治理方面迈出新里程碑。
该奖项是继公司在2024年获得“ESG报告典范奖”后再获殊荣，充分体现其在ESG道路上的持续精进。在满足合规的基础之上，ESG信息披露更是赢得全球客户、投资人、监管机构等利益相关方信任的战略支点。
为什么这很重要？在当今商业环境中，ESG信息透明披露已日渐成为竞争优势。药明生物持续披露各可持续发展议题的目标、举措及进展，包括企业治理、人才发展、温室气体减排等，以切实行动积极推动深度变革，致力于塑造生物药绿色研究、开发和生产新标准，引领行业负责任、可持续发展，赢得利益相关方信任。
陈智胜
博士
药明生物首席执行官
ESG委员会主席
透明是信任的基石。我们始终坚持公开分享ESG历程，希望携手全球合作伙伴和投资者，共同创造社会与环境的长期价值。荣获ESG披露奖，不仅是对我们努力的认可，更是对我们未来使命的鼓舞。我们将继续以更高标准推动负责任发展，引领行业迈向更加可持续的未来。
作为联合国全球契约组织（UNGC）和制药供应链倡议组织（PSCI）成员，药明生物积极倡导可持续发展的战略举措并赢得业界广泛认可。公司获得明晟（MSCI）最高AAA ESG评级、EcoVadis“铂金”评级、入选道琼斯可持续发展指数（DJSI）；荣登CDP气候变化、水安全和供应商参与度三大领域A级榜单；获评晨星Sustainalytics ESG“风险可忽略”最高评级以及“行业最高评级”与“区域最高评级”企业；入选富时社会责任指数系列；入选恒生ESG 50指数；ISS ESG评级“最佳”奖章认可，充分彰显了公司在可持续发展领域的卓越表现。
关于药明生物
药明生物（股票代码：2269.HK）是一家全球领先的合同研究、开发和生产（CRDMO）公司。公司通过开放式、一体化生物制药能力和技术赋能平台，提供全方位的端到端服务，帮助合作伙伴发现、开发及生产生物药，实现从概念到商业化生产的全过程，加速全球生物药研发进程，降低研发成本，造福病患。
药明生物在中国、美国、爱尔兰、德国和新加坡拥有超过12000名员工。通过药明生物的专业服务团队，以及先进技术和精深洞见，公司为客户提供高效经济的生物药解决方案。截至2025年6月底，药明生物帮助客户研发和生产的综合项目高达864个，其中包括24个商业化生产项目。
药明生物以可持续发展为长期业务增长的基石。公司持续推动绿色创新技术，为全球合作伙伴提供先进的端到端绿色CRDMO解决方案，同时在ESG方面不断取得卓越成就。秉承创造共享价值的理念，公司携手利益相关方构建可持续发展生态，通过负责任运营模式推动社会价值与生态效益双提升，实现全价值链的协同赋能。更多信息，请访问：www.wuxibiologics.com
ESG
esg@wuxibiologics.com
媒体关系
PR@wuxibiologics.com
Transparency Wins Trust! WuXi Biologics Recognized by Hong Kong ESG Reporting Awards 2025 for Outstanding ESG Disclosure
Hong Kong,
December 24, 2025
WuXi Biologics (2269.HK) has once again raised the bar for sustainability commitment and transparency. The company has been honored by the Hong Kong ESG Reporting Awards (HERA) 2025 for Outstanding ESG Disclosure, marking a new milestone in its dedication to openness and accountability.
This recognition follows last year's ESG Report Benchmark Award from HERA, verifying the consistency of WuXi Biologics' progressive ESG journey. Beyond assuring compliance, ESG reporting is a strategic lever that helps gain trust and strengthen confidence among global clients, investors, regulators, and other stakeholders.
Why does this matter? In today's business landscape, transparent ESG disclosure is a competitive advantage. WuXi Biologics' detailed reporting on its sustainability targets and progress – such as corporate governance, talent development and GHG emission reduction – reassures stakeholders that the company is driving meaningful change and shaping the future of Green CRDMO.
Dr. Chris Chen
Chief Executive Officer
Chairman of the ESG Committee
WuXi Biologics
Transparency is the cornerstone of trust. We firmly believe that openly sharing our ESG journey is essential, because only through collaboration can we help to create lasting value that contributes positively to society and the environment. Receiving the ESG Disclosure Award not only validates our efforts, but also inspires us to continue raising the bar as we lead the industry toward a more responsible and sustainable future.
As a participant of the United Nations Global Compact (UNGC) and the Pharmaceutical Supply Chain Initiative (PSCI), WuXi Biologics proactively advocates sustainability and has earned widespread recognitions for its efforts. The company was granted an MSCI AAA Rating; awarded an EcoVadis Platinum Medal; listed in the Dow Jones Sustainability Indices (DJSI); named to the CDP "A List" for Climate Change, Water Security, Supplier Engagement Assessment; given the highest negligible-risk rating by Sustainalytics, and recognized as a Sustainalytics industry and regional ESG top-rated company for five consecutive years; selected as a Constituent of the FTSE4Good Index Series; listed in the Hang Seng ESG 50 Index; and rated as Prime by ISS ESG Corporate Rating.
About
WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of June 30, 2025, WuXi Biologics is supporting 864 integrated client projects, including 24 in commercial manufacturing.
WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives green technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while consistently achieving excellence in Environment, Social and Governance (ESG). Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts and promote responsible practices that empower the entire value chain.
For more information about WuXi Biologics, please visit: www.wuxibiologics.com
Contacts
ESG
esg@wuxibiologics.com
Media
PR@wuxibiologics.com
注：本信息不构成药明生物的信息披露或投资建议
请点击右下角【爱心】，
并将公众号设为【星标】，
第一时间收到药明生物最新消息
